Infigratinib
- Generic Name
- Infigratinib
- Brand Names
- Truseltiq
- Drug Type
- Small Molecule
- Chemical Formula
- C26H31Cl2N7O3
- CAS Number
- 872511-34-7
- Unique Ingredient Identifier
- A4055ME1VK
- Background
Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infi...
- Indication
Infigratinib is indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.
- Associated Conditions
- Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas
- Associated Therapies
- -
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04197986
- Locations
- 🇺🇸
The Ohio State University College of Medicine, Columbus, Ohio, United States
🇺🇸Associated Medical Professionals - Syracuse, Syracuse, New York, United States
🇺🇸New Jersey Urology - Saddle Brook, Saddle Brook, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.